Heart Attack clinical trials at UC Irvine
3 in progress, 2 open to eligible people
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
open to eligible people ages 18 years and up
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.
Orange, California and other locations
Reducing Blood Pressure in Patients With High Cardiovascular Risk in the Safety-Net
open to eligible people ages 35 years and up
BP-REACH is a study of a team-based (pharmacist and health coach) program for lowering blood pressure for people with a prior stroke or heart attack in the Los Angeles Department of Health Services public healthcare system. The goal of this clinical trial is to test if this team based program is better at helping people reduce their blood pressure than usual care for people with prior heart attack or stroke. The main questions it aims to answer are: - Do people in the REACH BP program have lower blood pressure at 12 months compared to those getting usual care? - Do people in the REACH BP program have better Life's Essential 8 scores and patient experience compared to those getting usual care?
Downey, California and other locations
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Sorry, in progress, not accepting new patients
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).
Orange, California and other locations
Last updated: